抗HLA抗体可改良异基因造血干细胞移植患者的预后(国外英文资料).docVIP

抗HLA抗体可改善异基因造血干细胞移植患者的预后 HLA antibodies can improve the prognosis of patients with allogenic hematopoietic stem cell transplantation Chinese journal of hematology? The 2013-10-16? share Recent studies have shown that allogeneic hematopoietic stem cell transplantation (allo HSCT) patients resistant donor specific antibody (donor - specific antibodies, DSA), especially the resistance to human leukocyte antigen (human leukocyte antigen, HLA) antibodies. HLA is hematopoietic stem cell engraftment, hematopoietic reconstruction time delay and survive one of the most important factor, especially the resistance of donor specific HLA antibodies (DSHA) and HLA mismatch for recipients allo - HSCT is closely related to the failure, to lower survival significantly. The production of antihla antibodies has been linked to blood transfusion, pregnancy, transgenic transplantation and infection. Due to the height of the HLA gene polymorphism, even if the HLA - A, B, C, DRB1, DQB1 high-resolution genotyping in full for transplant recipients, may also be due to A common antigen epitope cross reaction and resistance to HLA antibodies, and the result of the HLA mismatch - DPB1 locus of HLA antibodies - DP. Therefore, the anti-hla antibody test should be an important indicator for screening donor and evaluating prognosis before clinical HSCT. Anti-hla-positive patients should actively reduce the pretreatment of antibody drops prior to transplantation, thereby improving the success rate of transplant and improving the prognosis of patients. We reviewed recent advances in the allo-hsct field of research on HLA antibodies. One. The causes, types and methods of the anti-hla antibody Anti HLA antibodies can have a variety of causes, existing research clearly expounds the resistance to the effect of HLA antibodies in blood transfusion medicine, anti HLA antibodies of the existence of a patient is one of the main reasons for platelet transfusion is invalid. On the other hand, the presence of HL